SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Home » Executive Leadership » Siddharth Mittal
Siddharth Mittal is an accomplished business leader with close to three decades of experience spanning business leadership, strategy, business transformation, strategic finance, mergers & acquisitions, and enterprise value creation, Siddharth is responsible for the Company’s strategic direction, business performance and operational excellence to drive long-term growth.
Prior to joining Syngene, Siddharth was with Biocon Limited since May 2013, where he joined as Chief Financial Officer before being appointed Managing Director and Chief Executive Officer in 2019. As CFO he played a pivotal role in strengthening the Company’s strategic finance agenda, leading strategic biosimilar partnerships with global partners, and driving shareholder value. He subsequently led the strategic spin-off of Biocon Biologics into an independent global biosimilars company enabling greater focus across the biosimilars and generics businesses. He also played a key role in the Group’s corporate restructuring, including the US$ 1 billion Qualified Institutional Placement (QIP) and the consolidation of the biosimilars and generics businesses.
As Managing Director and CEO, Siddharth led Biocon’s diversified biopharmaceutical business, with responsibility spanning both the Generics and Novel Biologics portfolios. During this period, he transformed the Generics business by expanding its global manufacturing platform, strengthening commercial partnerships, and advancing its complex formulations portfolio – including the commercialization of the Company’s GLP-1 portfolio in key markets. He also oversaw Biocon’s innovation-led Novel Biologics business, guiding the progression of its pipeline and partnerships, while reinforcing the Company’s position as an innovation-led global biopharmaceutical enterprise.
He currently serves as Co-President of IPSO (Innovative Pharmaceutical Services Organisation) and is a National Executive Committee member of FICCI.
Earlier in his career Siddharth worked with the audit practice of S.R. Batliboi & Co (an EY member firm) and thereafter held progressively senior finance positions at Cambridge Solutions and Symphony Teleca in the United States.
Siddharth holds a Bachelor of Commerce degree from Symbiosis College of Arts and Commerce, Pune. He is a Chartered Accountant from the Institute of Chartered Accountants of India and a Certified Public Accountant (CPA) from Colorado, USA. He is recognized for his strategic mindset, commercial acumen and execution-focused leadership style, along with a strong record of building high-performing teams, driving business transformation and creating sustainable value for customers, partners and shareholders.